Bionomics Limited
31 Dalgleish Street
Thebarton
South Australia
5031
Australia
Tel: 618-8354-6100
Fax: 618-8354-6199
Website: http://www.bionomics.com.au/
Email: info@bionomics.com.au
101 articles with Bionomics Limited
-
Further Data Analysis of Bionomics’ Phase 2 Post Traumatic Stress Disorder Trial Shows the Potential for Significant Patient Benefit When Drug Exposure Is Adequate
2/18/2019
Bionomics Limited announces that an additional data analysis conducted in Sweden by Pharmetheus AB showed a statistically significant response when drug exposure versus response was measured in the Phase 2 PTSD Trial.
-
Yesterday, top-line data from Bionomics Limited revealed details of the biopharmaceutical company’s Phase II clinical trial of BNC210 in regards to patients with post traumatic stress disorder.
-
Bionomics’ Phase 2 Post Traumatic Stress Disorder Trial Results
10/2/2018
Trial did not meet primary endpoint of decrease in PTSD symptoms as measured by CAPS-5 at 12 weeks
-
Commencement of BNC210 Phase 2 Clinical Trial for the Treatment of Agitation
5/24/2018
Treatment of agitation in the elderly in hospital and nursing home settings represents a rapid potential path to market for BNC210 No currently approved treatments and significant unmet medical need
-
Bionomics Limited: A Company With Deals On The Horizon
7/5/2017
-
Bionomics Limited Release: New BNC105 Clinical Trial In Combination With Keytruda
2/20/2017
-
Bionomics Limited To Receive Milestone Payment From Merck & Co. For Initiation Of Phase I Clinical Study Of Candidate Alzheimer's Treatment
2/3/2017
-
Bionomics Limited Announces Positive Results From Phase 2 Trial Of BNC210 In Generalized Anxiety Disorder
9/21/2016
-
Bionomics Limited Release: Post Traumatic Stress Disorder Identified As Major New Market Opportunity For BNC210
12/8/2015
-
Bionomics Limited And MSD Hosting Cognition And Alzheimer's Symposium Featuring Australian And US Speakers
11/13/2015
-
Bionomics Limited To Present Preclinical Data On BNC105 At AACR-NCI-EORTC International Conference
11/4/2015
-
Bionomics Limited Announces Extension Of Strategic Collaboration With Merck & Co. For The Discovery And Development Of Novel Pain Medications
10/8/2015
-
Bionomics Limited Reports Positive Data From Phase 1 Multiple Ascending Dose Trial Of BNC210 For Anxiety And Depression
9/16/2015
-
Bionomics Limited Release: Successful BNC101 IND Submission Paves Way For Development Of Promising Cancer Stem Cell Drug Candidate
8/31/2015
-
Bionomics Limited Files Patent For Use Of BNC105 In Combination With PD-1 And CTLA-4 Immuno-Oncology Antibodies
6/15/2015
-
Bionomics Limited Initiates Phase II Clinical Trial Of BNC210 For Treatment Of Anxiety
4/20/2015
-
Bionomics Limited Showcases Oncology Drug Development Programs At 2015 American Association for Cancer Research Annual Meeting
4/17/2015
-
Bionomics Limited Release: BNC105 Biomarker Data To Be Presented At Asian Oncology Conference
4/10/2015
-
Bionomics Limited Begins Trading On OTCQX Marketplace
3/2/2015
-
Bionomics Limited Release: New BNC105 Biomarker Data To Be Presented At US Cancer Conference
2/27/2015